Q1 EPS Estimates for Sensus Healthcare Cut by HC Wainwright

Sensus Healthcare, Inc. (NASDAQ:SRTS) – Equities researchers at HC Wainwright cut their Q1 2025 earnings per share estimates for shares of Sensus Healthcare in a research note issued to investors on Monday, February 10th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of $0.11 per share for the quarter, down from their previous estimate of $0.14. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.71 per share. HC Wainwright also issued estimates for Sensus Healthcare’s Q3 2025 earnings at $0.10 EPS and Q4 2025 earnings at $0.16 EPS.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Wednesday, February 5th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%.

SRTS has been the subject of several other reports. Maxim Group increased their price target on Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Lake Street Capital assumed coverage on Sensus Healthcare in a report on Friday, January 31st. They issued a “buy” rating and a $18.00 price objective for the company.

Sensus Healthcare Price Performance

Shares of NASDAQ SRTS opened at $5.65 on Tuesday. The business has a 50-day moving average of $7.28 and a 200-day moving average of $6.88. The stock has a market capitalization of $92.60 million, a price-to-earnings ratio of 14.13 and a beta of 1.24. Sensus Healthcare has a fifty-two week low of $2.91 and a fifty-two week high of $9.33.

Institutional Investors Weigh In On Sensus Healthcare

Hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. bought a new stake in Sensus Healthcare in the fourth quarter valued at approximately $27,000. Truvestments Capital LLC bought a new stake in Sensus Healthcare in the 3rd quarter valued at $32,000. IFP Advisors Inc bought a new stake in Sensus Healthcare in the 4th quarter valued at $95,000. Cubist Systematic Strategies LLC bought a new position in Sensus Healthcare during the second quarter worth $156,000. Finally, XTX Topco Ltd boosted its position in Sensus Healthcare by 76.0% during the third quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock worth $183,000 after purchasing an additional 13,619 shares during the period. 25.30% of the stock is currently owned by institutional investors and hedge funds.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.